enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Leuprorelin - Wikipedia

   en.wikipedia.org/wiki/Leuprorelin

   Lupron injection was approved by the FDA for treatment of advanced prostate cancer on 9 April 1985. [45] [4] [43] [44] Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on 26 January 1989. [8]

3. Comparison of bicalutamide with other antiandrogens

   en.wikipedia.org/wiki/Comparison_of_bicalutamide...

   [78] [79] [80] Of the SAAs, CPA is the only one that has been widely used in the treatment of prostate cancer. [28]: 488 As antiandrogens, the SAAs have largely been replaced by the NSAAs and are now rarely used in the treatment of prostate cancer, due to the superior selectivity, efficacy, and tolerability profiles of NSAAs.

4. Gonadotropin-releasing hormone agonist - Wikipedia

   en.wikipedia.org/wiki/Gonadotropin-releasing...

   A gonadotropin-releasing hormone agonist (GnRH agonist) is a type of medication which affects gonadotropins and sex hormones. [1] They are used for a variety of indications including in fertility medicine and to lower sex hormone levels in the treatment of hormone-sensitive cancers such as prostate cancer and breast cancer, certain gynecological disorders like heavy periods and endometriosis ...

5. Experts Face Off on Prostate Cancer Drugs - AOL

   www.aol.com/2010/04/11/should-men-take-drug-to...

   For premium support please call: 800-290-4726 more ways to reach us

6. Medical uses of bicalutamide - Wikipedia

   en.wikipedia.org/wiki/Medical_uses_of_bicalutamide

   Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...

7. Relugolix - Wikipedia

   en.wikipedia.org/wiki/Relugolix

   Relugolix was approved for the treatment of uterine fibroids in Japan in January 2019. [12] [13] It was the second orally active GnRH antagonist to be introduced for medical use, following elagolix (brand name Orilissa) in July 2018. [12] [17] Relugolix was approved for the treatment of prostate cancer in the United States on 18 December 2020 ...